≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at 2-8°C,Protected from light,Desiccated Ships Wet ice Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Senazodan (MCI 154) (hydrochloride), as a Ca 2+ sensitiser, shows inhibition effect on PDE III
In Vitro
Senazodan (hydrochloride) seems to affect directly the actin-myosin crossbridge kinetics, and increases myosin ATPase activity. Senazodan (hydrochloride) produces a concentration-dependent increase in tension development. Senazodan (hydrochloride) enhances Ca 2+ binding to myofilaments and to purified cardiac troponin C. Senazodan (hydrochloride) also enhances contractility in guinea-pig papillary muscles by inhibiting PDE III.Senazodan (0.1 nM~0.1 mM) (hydrochloride) shows that the contractile response of superior mesenteric arterie (SMA) to norepinephrine (NE) after hemorrhagic shock is significantly decreased as compared with the normal control group. Senazodan (0.01 mM) (hydrochloride) pretreatment prevents the effects of Ang II, and the concentration-response curve of Ca 2+ is shifted to the right as compared with Ang II-alone group. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Senazodan (0.1~2.0 mg/kg; left femoral vein catheterization infusion) (hydrochloride) decreases the pressor effect of norepinephrine (NE). Senazodan (0.1 mg/kg; i.v.) (hydrochloride) makes LVSP, IP, MC, and Lo all increased significantly, while heart rate is not obviously changed and left ventricular end-diastolic pressure (LVEDP) is reduced remarkably. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Wistar rats (200~250 g)Dosage: 0.1~2.0 mg/kg Administration: Left femoral vein catheterization infusion Result: Decreased the pressor effect of norepinephrine (NE). Animal Model: RabbitsDosage: 0.1 mg/kg Administration: I.v. Result: LVSP, IP, MC, and Lo all were increased significantly while heart rate was not obviously changed and left ventricular end-diastolic pressure (LVEDP) was reduced remarkably.
Form:Solid
IC50& Target:PDE III
| Canonical Smiles | C1CC(=O)NN=C1C2=CC=C(C=C2)NC3=CC=NC=C3.Cl |
|---|---|
| Isomeric SMILES | C1CC(=O)NN=C1C2=CC=C(C=C2)NC3=CC=NC=C3.Cl |
| PubChem CID | 123941 |
| Molecular Weight | 302.76 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Solubility | DMSO : 50 mg/mL (165.15 mM; Need ultrasonic) H2O : 25 mg/mL (82.57 mM; Need ultrasonic) |
|---|---|
| Molecular Weight | 302.760 g/mol |
| XLogP3 | |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 3 |
| Exact Mass | 302.093 Da |
| Monoisotopic Mass | 302.093 Da |
| Topological Polar Surface Area | 66.400 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 368.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 2 |
